Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2293211 | 1.00 | KDM4E (0.39) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL1722702 | 1.00 | KDM4E (0.39) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL1711908 | 0.84 | KDM4E (0.39) | KDM4EHTTALDH1A1HPGDTDP1 | |
| SCHEMBL1712708 | 0.84 | KDM4E (0.39) | KDM4EHTTALDH1A1HPGDTDP1 | |
| SCHEMBL1723632 | 0.83 | KDM4E (0.38) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL1723633 | 0.83 | KDM4E (0.38) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL1723635 | 0.83 | KDM4E (0.38) | KDM4EHTTALDH1A1HPGDAAK1 | |
| SCHEMBL1711963 | 0.83 | MTNR1A (0.46) | KDM4EALDH1A1 | |
| SCHEMBL1712314 | 0.83 | MTNR1A (0.46) | KDM4EALDH1A1 | |
| SCHEMBL15707645 | 0.81 | KCNH2 (0.40) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822114-B2 | Tricyclic oxazolidinone antibiotic compounds | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-11-21 | — | — | US | disclosed |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-08-18 | — | — | US | disclosed |
| US-9346804-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-05-24 | — | — | US | disclosed |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-05-22 | — | — | US | disclosed |
| US-8618092-B2 | Tricyclic oxazolidinone antibiotic compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-12-31 | — | — | US | disclosed |
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195961-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | HRH3, OXA1L, HRH1 | KDM4E 3061/4885HTT 2498/4885ALDH1A1 3208/4885 |
| US-20160237088-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | H1-3, HRH3, HRH4 | KDM4E 2290/4885HTT 2075/4885ALDH1A1 3572/4885 |
| US-20140142093-A1 | TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS | OXA1L, H1-3, NGLY1 | KDM4E 2854/4885HTT 2206/4885ALDH1A1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.